MedCity News
Evox has big pharma partners. Now it has $95M to bring its own drugs to the clinic
In the past year, Evox Therapeutics has inked alliances with two big pharma companies. The Series C financing now positions the biotech to advance to the clinic with its own exosome-based therapies.
Shares0
Cells in the body share material via tiny vesicles that shuttle between them, carrying molecular payloads from one cell to another. Evox Therapeutics is developing medicines that leverage this mechanism as way of accessing cells and tissues that are beyond the reach of current drug technologies.
The biotech has research partnerships with two large pharmaceutical companies. Now it has $95.4 million to advance into clinical testing with several rare disease drug candidates. Redmile Group led the Series C round of funding.
Share this article
Share this article
OXFORD, England, Feb. 18, 2021 /PRNewswire/ Evox Therapeutics Ltd ( Evox or the Company ), a leading exosome therapeutics company, today announces that it has raised £69.2 million ($95.4 million) in a Series C financing round.
The financing was significantly oversubscribed with high demand from both existing and new investors. The Series C financing was led by Redmile Group who were joined by new investors OrbiMed and Invus. In addition to Redmile, all existing Series B investors reinvested, including major investors Oxford Sciences Innovation (OSI), GV (formerly Google Ventures) and Cowen Healthcare Investments. Eli Lilly, also converted a $10 million convertible note, that formed part of our 2020 collaboration agreement with them, into equity as part of this round.
Evox Therapeutics : completes £69 2 million Series C financing marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Evox raises £69 2m to advance exosome-based therapeutics pipeline pharmatimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmatimes.com Daily Mail and Mail on Sunday newspapers.